Detalles de la búsqueda
1.
CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Clin Infect Dis
; 76(11): 1879-1888, 2023 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36722329
2.
Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
Medicine (Baltimore)
; 99(47): e23335, 2020 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217873
3.
Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.
Open Forum Infect Dis
; 7(11): ofaa404, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33204746
Resultados
1 -
3
de 3
1
Próxima >
>>